Gap Inc vs Medpace Holdings Inc — how do they compare? Gap Inc trades at $23.33 (market cap $8.29B), while Medpace Holdings Inc trades at $602 (market cap $16.87B). The key difference: Medpace Holdings Inc is far larger — about 2× Gap Inc's market cap, and Gap Inc pays a 2.96% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Medpace Holdings Inc for 14 Days on average.
| GAP | MEDP | |
|---|---|---|
Market Cap | $8.29B | $16.87B |
Volume | 5,470,564 | 207,570 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $630.19 |
52-Week Low | $18.35 | $393.42 |
Typical Hold Time | 37 Days | 14 Days |
Enterprise Value | $11.53B | $16.48B |
Dividend Yield | 2.96% | — |
Signals from Pluang's Aura AI — not financial advice
Gap trades at $23.36, down 1.81% for the day, with a bullish technical outlook from moving averages. The company shows strong profitability with a 43.26% gross margin and 8.14% net margin, supported by recent earnings beats. Revenue has stabilized around $15B, and cash flow from operations remains robust at $1.49B. Recent news highlights brand revitalization efforts, including music partnerships and board appointments, signaling strategic moves to engage customers.
The outlook is positive given low valuations (P/E 7.11, P/S 0.58) and analyst consensus target of $25.67, implying upside. Risks include reliance on Old Navy's turnaround and competitive pressures. Institutional activity is mixed, with some funds reducing stakes while others increase positions, reflecting cautious optimism.
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →